NCT02625714View on ClinicalTrials.gov

Safety/Tolerability and Pharmacokinetic Study of SID142

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Arterial Occlusive Diseases
Interventions
DRUG

Renexin®

Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid

DRUG

SID142

Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT02625714 - Safety/Tolerability and Pharmacokinetic Study of SID142 | Biotech Hunter | Biotech Hunter